secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001200375-23-000022
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis reduces headcount 25%, extends cash runway to mid-2026; Q2 preliminary revenue $21-22M
--------------------------------------------------------------------------------

- Workforce reduction of ~25% (approx. $2.9M expense in Q3 2023); expects completion by Sep 30, 2023.
- Discontinuing investment in Biotherapeutics programs, consolidating to Redwood City HQ.
- Preliminary Q2 2023 total revenue $21-22M (product $11-12M, R&D $10M); cash $92.1M.
- Reiterates 2023 product revenue guidance $30-35M; lowers R&D revenue guidance to $21-24M (from $28-33M).
- Expects cash runway to mid-2026; anticipates Pharma Manufacturing growth in 2024; ECO Synthesis demo by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/0001200375-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/cdxs-20230720.htm
  HTML page:      https://secwatch.observer/filing/0001200375-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer